In this section of the page, you will find all the information you need to understand how Vivoryon Therapeutics (VVY) dividends work. In addition, you will be able to consult the payment date, the ex-dividend date, the last day to be entitled to the payment, the money to be received per share, the yield and any other doubts that may arise.
There is no upcoming dividend defined for Vivoryon Therapeutics.
There is no set last day on which buying Vivoryon Therapeutics shares generates the possibility of earning dividends.
There has been no final dividend for Vivoryon Therapeutics.
Vivoryon Therapeutics N.V., listed on the German stock exchange and in the Netherlands in Amsterdam using the stock symbol VVY, has not paid dividends to its shareholders so far, but it should be noted that the company was established fairly recently and is still in a growth phase, so the strategy regarding the use of this interest is to invest it in its own development, which may change once it has reached maturity in the market.
Join +33,000 investors who get notifications, analysis and news.
Payout Ratio Vivoryon Therapeutics Dividends
Dividend calendar of Vivoryon Therapeutics
There is no Dividend Calendar of Vivoryon Therapeutics defined for 2023.
Historical annual dividend yields of Vivoryon Therapeutics
Dividend yield of Vivoryon Therapeutics vs. the sector
Dividend yield history in Vivoryon Therapeutics
Dividend history of Vivoryon Therapeutics
Vivoryon Therapeutics has never distributed dividends, so it has an empty dividend history.
Vivoryon Therapeutics dividend capture strategy
Information about Vivoryon Therapeutics
Vivoryon Therapeutics N.V. is a biopharmaceutical company engaged in clinical and preclinical trials, as well as research and development activities, creating innovative small molecule drugs for the purpose of treating serious and life-threatening diseases such as cancer or Alzheimer's disease.
Its main product is varoglutamstat, which is in the second phase of studies and development, developed to combat Alzheimer's disease, has a delicate use of proteins, enzymes and other components that act in the center of human learning and memory, regulating brain activity.
Its headquarters are located in Germany, it was founded in 2020, although in 2021 they entered into a strategic partnership with Simcere Pharmaceutical Group Ltd, licensed in China, which allows them to develop and commercialize drugs that have been manufactured to treat brain problems, specifically varoglutamstat, an agreement that, in addition to allowing them to export their products, generated a significant contribution to their income.
In addition, the company has a complete line of inhibitors, mainly for oral consumption, that help minimize the effects of cancer, fibrosis and some inflammatory diseases, such as the PBD-C06 antibody, which is still in the preclinical stage.
Frequently asked questions about Vivoryon Therapeutics dividends
Vivoryon Therapeutics is listed on the Bolsa de Amsterdam and is part of the ASCX.
Vivoryon Therapeutics has the Ticker or stock code VVY.
Vivoryon Therapeutics belongs to the Health Care sector and the Biotechnology industry.
The CEO of Vivoryon Therapeutics in 2023 is Mr. Florian Schmid.
At this moment, the value of a Vivoryon Therapeutics share is 7.67€.
Vivoryon Therapeutics does not have a growing dividend program. Dividends have not shown a steady growth in the last 5 years.